BGB-A317-210

Completed

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Beigene Study ID info

BGB-A317-210

ClinicalTrials.gov ID info

EudraCT Number info

2019-002105-22

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents